NASDAQ:RYTM Rhythm Pharmaceuticals Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Rhythm Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $22.26 -0.15 (-0.67 %) (As of 09/29/2020 03:59 PM ET) Add Compare Share Today's Range$21.85Now: $22.26▼$22.7950-Day Range$18.13MA: $24.65▼$30.6152-Week Range$12.99Now: $22.26▼$32.24Volume5,925 shsAverage Volume252,997 shsMarket Capitalization$982.09 millionP/E RatioN/ADividend YieldN/ABeta1.18 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Rhythm Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic disorders that result in life-threatening metabolic disorders. The company's lead product candidate is setmelanotide, a melanocortin-4 receptor agonist peptide, which is in Phase III clinical trials to treat pro-opiomelanocortin (POMC) and leptin receptor deficiency obesity, and Bardet-Biedl and Alström syndrome; and is in Phase II clinical trials for treating POMC heterozygous deficiency obesity and POMC epigenetic disorders. It is also developing RM-853, an orally available ghrelin o-acyltransferase inhibitor that is in preclinical development for Prader-Willi syndrome. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.Read More Beat the Market (BTM) Rank™ 3.3 Analyst's Opinion Consensus RatingRhythm Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 5 buy ratings, no hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $32.67, Rhythm Pharmaceuticals has a forecasted upside of 46.8% from its current price of $22.26.Amount of Analyst CoverageRhythm Pharmaceuticals has only been the subject of 4 research reports in the past 90 days. Previous Next 2.5 Community Rank Outperform VotesRhythm Pharmaceuticals has received 228 “outperform” votes. (Add your “outperform” vote.)Underperform VotesRhythm Pharmaceuticals has received 223 “underperform” votes. (Add your “underperform” vote.)Community SentimentRhythm Pharmaceuticals has received 50.55% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Rhythm Pharmaceuticals and other stocks. Vote “Outperform” if you believe RYTM will outperform the S&P 500 over the long term. Vote “Underperform” if you believe RYTM will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldRhythm Pharmaceuticals does not currently pay a dividend.Dividend GrowthRhythm Pharmaceuticals does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Rhythm Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,463,243.00 in company stock.Percentage Held by InsidersOnly 9.49% of the stock of Rhythm Pharmaceuticals is held by insiders.Percentage Held by Institutions92.97% of the stock of Rhythm Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Rhythm Pharmaceuticals are expected to grow in the coming year, from ($3.31) to ($1.98) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Rhythm Pharmaceuticals is -6.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Rhythm Pharmaceuticals is -6.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRhythm Pharmaceuticals has a P/B Ratio of 3.48. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.3Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.49 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RYTM Previous Symbol CUSIPN/A CIK1649904 Webwww.rhythmtx.com Phone857-264-4280Debt Debt-to-Equity Ratio0.01 Current Ratio15.96 Quick Ratio15.96Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.40 per share Price / Book3.48Profitability EPS (Most Recent Fiscal Year)($3.86) Net Income$-140,730,000.00 Net MarginsN/A Return on Equity-59.07% Return on Assets-53.52%Miscellaneous Employees54 Outstanding Shares44,119,000Market Cap$982.09 million Next Earnings Date11/6/2020 (Estimated) OptionableOptionable $22.26 -0.15 (-0.67 %) (As of 09/29/2020 03:59 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive RYTM News and Ratings via Email Sign-up to receive the latest news and ratings for RYTM and its competitors with MarketBeat's FREE daily newsletter. Rhythm Pharmaceuticals (NASDAQ:RYTM) Frequently Asked Questions How has Rhythm Pharmaceuticals' stock price been impacted by COVID-19? Rhythm Pharmaceuticals' stock was trading at $15.00 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, RYTM stock has increased by 48.4% and is now trading at $22.26. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Rhythm Pharmaceuticals? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rhythm Pharmaceuticals in the last year. There are currently 1 sell rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Rhythm Pharmaceuticals. When is Rhythm Pharmaceuticals' next earnings date? Rhythm Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Friday, November 6th 2020. View our earnings forecast for Rhythm Pharmaceuticals. How were Rhythm Pharmaceuticals' earnings last quarter? Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) released its quarterly earnings results on Monday, August, 3rd. The company reported ($0.71) earnings per share for the quarter, topping the consensus estimate of ($0.83) by $0.12. View Rhythm Pharmaceuticals' earnings history. What price target have analysts set for RYTM? 6 analysts have issued twelve-month price targets for Rhythm Pharmaceuticals' stock. Their forecasts range from $18.00 to $43.00. On average, they expect Rhythm Pharmaceuticals' stock price to reach $32.67 in the next year. This suggests a possible upside of 46.8% from the stock's current price. View analysts' price targets for Rhythm Pharmaceuticals. Who are some of Rhythm Pharmaceuticals' key competitors? Some companies that are related to Rhythm Pharmaceuticals include Evotec (EVTCY), FibroGen (FGEN), Allakos (ALLK), Turning Point Therapeutics (TPTX), Biohaven Pharmaceutical (BHVN), ChemoCentryx (CCXI), Amicus Therapeutics (FOLD), Insmed (INSM), Principia Biopharma (PRNB), Global Blood Therapeutics (GBT), HYPERA S A/S (HYPMY), TG Therapeutics (TGTX), PTC Therapeutics (PTCT), Reata Pharmaceuticals (RETA) and SAGE Therapeutics (SAGE). View all competitors. What other stocks do shareholders of Rhythm Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Rhythm Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Gilead Sciences (GILD), Viking Therapeutics (VKTX), Kadmon (KDMN), Sarepta Therapeutics (SRPT), Agile Therapeutics (AGRX), Amarin (AMRN), Exelixis (EXEL) and Intra-Cellular Therapies (ITCI). Who are Rhythm Pharmaceuticals' key executives? Rhythm Pharmaceuticals' management team includes the following people: Dr. Keith Michael Gottesdiener, Pres, CEO & Director (Age 65)Mr. Hunter C. Smith, CFO & Treasurer (Age 50)Ms. Nithya Desikan, Chief Commercial Officer (Age 40)Mr. Leonardus H.T. van der Ploeg, Chief Scientific Officer (Age 64)Mr. Simon D. Kelner, Chief HR Officer (Age 46) When did Rhythm Pharmaceuticals IPO? (RYTM) raised $100 million in an IPO on Thursday, October 5th 2017. The company issued 6,700,000 shares at $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen acted as the underwriters for the IPO and Needham was co-manager. What is Rhythm Pharmaceuticals' stock symbol? Rhythm Pharmaceuticals trades on the NASDAQ under the ticker symbol "RYTM." How do I buy shares of Rhythm Pharmaceuticals? Shares of RYTM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Rhythm Pharmaceuticals' stock price today? One share of RYTM stock can currently be purchased for approximately $22.26. How big of a company is Rhythm Pharmaceuticals? Rhythm Pharmaceuticals has a market capitalization of $982.09 million. The company earns $-140,730,000.00 in net income (profit) each year or ($3.86) on an earnings per share basis. Rhythm Pharmaceuticals employs 54 workers across the globe. What is Rhythm Pharmaceuticals' official website? The official website for Rhythm Pharmaceuticals is www.rhythmtx.com. How can I contact Rhythm Pharmaceuticals? Rhythm Pharmaceuticals' mailing address is 222 BERKELEY STREET 12TH FLOOR, BOSTON MA, 02116. The company can be reached via phone at 857-264-4280 or via email at [email protected] This page was last updated on 9/29/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
